# Sanegene Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sanegene-bio

- Industry: Biotechnology
- Headquarters: Woburn, US
- Website: www.sanegenebio.com
- Total disclosed funding: $270M
- Latest round: Series B (Dec 8, 2025)
- Investors on record: 26

## About

Based in Massachusetts, USA and founded in 2021, Suzhou Sanegene Bio Inc., trading as Sanegene Bio, operates as a pharmaceutical developer dedicated to developing novel RNAi therapeutics. The founder and CEO of the company, Weimin Wang has worked at Dicerna Pharmaceuticals. The CSO of the company, Shiyu Wang has worked in Ionis Pharmaceutical and Dicerna Pharmaceuticals. In December 2025, Sanegene Bio raised USD 110 million in series B funding from Sino Biopharmaceutical Limited, Legend Capital, Vivo Capital, Invus Financial Advisors, SymBiosis Capital Management, Suzhou Capital Group, Trumed Investment Management, Hainan Zhenmai Private Equity Fund Management, Lake Bleu Capital, Eli Lilly & Company, GL Ventures and K2 Venture Partners, Hillhouse Investment, Qiming Venture Partners, TF Capital, Oriza FoFs, and NLVC.



The company mainly develops RNAi therapeutics and pharmaceuticals through a chemical modification platform and hepatic and extrahepatic delivery platforms. The first RNAi drug SGB-3403 has entered the clinical stage, which is for the treatment of hypercholesterolemia.

The company's revenue is generated by providing RNAi therapeutics and pharmaceuticals. 

The company plans to use the December 2025 funding to leverage the company's globally leading RNAi drug development platform to advance its clinical-stage pipeline into registration studies and accelerate the development of its pipeline across multiple therapeutic areas.

## Funding rounds

- Series B, Dec 8, 2025, $110M — Legend Capital, Vivo Capital, Qiming Venture Partners, NLVC, Sino Biopharmaceutical Limited, Hillhouse Investment, Invus Financial Advisors, Eli Lilly & Company, TF Capital, GL Ventures, Lake Bleu Capital, Oriza FoFs, SymBiosis Capital Management, Suzhou Capital Group, Trumed Investment Management, K2 Venture Partners, Hainan Zhenmai Private Equity Fund Management
- Series A, Dec 1, 2023, $80M — Qiming Venture Partners, NLVC, TEDA Venture Capital, K2VC, YuanBio Venture, TF Capital, Alwin Capital, Shenzhen Capital Real Estate Fund, Xiamen C&D Emerging Industry Equity Investment, Shanghai Healthcare Capital, Oriza FoFs, Lingang Lanwan Fund, Tencent Investment
- Series A, Dec 1, 2021, $80M — Qiming Venture Partners, K2VC, TF Capital, Alwin Capital, Lingang Lanwan Fund

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- K2VC (https://capitalatlas.ai/funds/k2vc) — Series A
- TF Capital — Series A, Series B
- Alwin Capital — Series A
- Lingang Lanwan Fund — Series A
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A, Series B
- TEDA Venture Capital (https://capitalatlas.ai/funds/teda-venture-capital) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series A
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series A
- Oriza FoFs (https://capitalatlas.ai/funds/oriza-fofs) — Series A, Series B
- Tencent Investment — Series A
- Legend Capital — Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Sino Biopharmaceutical Limited — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- Invus Financial Advisors (https://capitalatlas.ai/funds/invus-financial-advisors) — Series B
- Eli Lilly & Company — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series B
- SymBiosis Capital Management (https://capitalatlas.ai/funds/symbiosis-capital-management) — Series B
- Suzhou Capital Group — Series B
- Trumed Investment Management — Series B
- K2 Venture Partners — Series B
- Hainan Zhenmai Private Equity Fund Management (https://capitalatlas.ai/funds/hainan-zhenmai-private-equity-fund-management) — Series B